Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis

Archives of Dermatological Research

Volumn 304, Issue 6, 2012, Pages 433-441

  Feuerhahn, Julia ^a   Blome, Christine ^a   Radtke, Marc ^a   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Patient Benefit Index; Patient reported outcomes; Patientrelevant benefit; Psoriasis; Questionnaire

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; HEALTH CARE QUALITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT BENEFIT INDEX; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK BENEFIT ANALYSIS; SKIN DISEASE; VALIDATION STUDY; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSORIASIS; QUESTIONNAIRES;

EID: 84864755304     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1256-y     Document Type: Article

References (45)

1. Augustin M, Amon U, Braathen L, Bullinger M, Gieler U, Klein GF, Schultz-Amlung W (2004) Assessment of quality of life in dermatology. J Dtsch Dermtol Ges 2(9):802-806
2. Augustin M, Blome C, Zschocke I, Schäfer I, Koenig S, Rustenbach SJ, Herberger K (2012) Benefit evaluation in the therapy of chronic wounds from the patients' perspective: development and validation of a new method. Wound Rep Reg 20:8-14
3. Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I (2008) Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology 217:101-106
4. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633-636
5. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216:366-372
6. Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I, Reusch M, Mielke V, Rustenbach SJ (2009) Patient benefit index: a novel approach in patient-defined outcomes measurement for skin disease. Arch Dermatol Res 301:561-571
7. Augustin M, Radtke M (2008) Health economic issues in psoriasis. Expert Rev Dermatol 3(4):19-23
8. Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ (2008) Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges 6:113-120
9. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M (2010) Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147-151
10. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M (2008) Quality of psoriasis care in Germanyresults of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640-645
11. Augustin M, Schäfer I, Rabini S, Lee-Seifert C, Radtke M, Rustenbach SJ (2009) Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit. Dermatology 218:255-259
12. Berger K, Ehlken B, Kugland B, Augustin M (2005) Cost-ofillness in patients with moderate and severe chronic psoriasis vulgaris in Germany. JDDG 3:511-518
13. Blome C, Augustin M, Behechtnejad J, Rustenbach SJ (2011) Dimensions of patients needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res 303:11-17
14. Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, Ständer S (2009) Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 161:1143-1148
15. Blome C, Maares J, Diepgen T, Rustenbach SJ, Augustin M (2009) Measurement of patient-relevant benefits in the treatment of chronic hand eczema: a novel approach. Contact Dermatitis 61:39-45
16. Blome C, Simianer S, Purwins S, Laas A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221:154-159
17. Bowling A (1995) Measuring disease: a review of disease-specific quality of life measurement scales. Open University Press, Buckingham
18. Brock D (1996) Quality of life measures in health care and medical ethics. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 487-510
19. Clark MS, Caudrey DJ (1983) Evaluation of rehabilitation services: the use of goal attainment scaling. Int Rehabil Med 5(1):41-45
20. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Schäfer G, EUROPSO Patient Survey Group (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155:729-736
21. Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210-216
22. Fisher K, Hardie RJ (2002) Goal attainment scaling in evaluating a multidisciplinary pain management programme. Clin Rehabil 16:871-877
23. Franzke N, Schäfer I, Jost K, Blome C, Rustenbach SJ, Reich K, Reusch M, Maurer M, Augustin M (2011) A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 66:665-670
24. Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157(4):238-244
25. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143:1493-1499
26. Greaves MW, Weinstein GD (1995) Treatment of psoriasis. N Engl J Med 332:581-588
27. Guyatt G, Walter S, Norman G (1987) Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 40:171-178
28. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36(5):551-559
29. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M (2010) Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 24(9):989-1004
30. Kiresuk T, Sherman R (1968) Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J 4:443-453
31. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137:280-284
32. Lienert G, Raatz U (1998) Testaufbau und Testanalyse. Beltz, Weinheim
33. Ottenbacher KJ, Cusick A (1990) Goal attainment scaling as a method of clinical service evaluation. Am J Occup Ther 44:519-525
34. Radtke MA, Augustin M (2008) Economic considerations in psoriasis management. Clin Dermatol 26:424-431
35. Rockwood K, Howlett S, Stadnyk K, Carver D, Powell C, Stolee P (2003) Responsiveness of goal attainment scaling in randomized controlled trial of comprehensive geriatric assessment. J Clin Epidemiol 56:736-743
36. Rushton PW, Miller WC (2002) Goal attainment scaling in the rehabilitation of patients with lower-extremity amputations: a pilot study. Arch Phys Med Rehabil 83:771-775
37. Schaefer I, Zimmer L, Rustenbach SJ, Augustin M (2008) Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 217:169-172
38. Smith G (1988) Measuring health: a practical approach. Chichester, New York
39. Sohn S, Schoeefski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212:137-144
40. Steffanowski A, Lichtenberg S, Schmidt J, Huber C, Wittmann WW, Nübling R (2004) Ergebnisqualität psychosomatischer Rehabilitation: zielerreichungsskalierung auf der Basis einer strukturierten Therapiezielliste. Rehabilitation 43:219-232
41. Steinbook RM, Jacobson AF, Mosher JC, Davies DL (1977) The goal attainment scale: an instructional guide for the delivery of social reinforcement. Arch Gen Psychiatry 34:923-926
42. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9:136-139
43. Zentner A, Velasco-Garrido M, Busse R (2005) Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. GMS Health Technol Assess (Internet). 2005 Nov 15 (cited 2009 Aug 19);1: Doc09(20051115). Available from: http://www.egms.de/dynamic/en/journals/hta/volume1.htm
44. Zschocke I, Hammelmann U, Augustin M (2005) Therapeutischer Nutzen in der dermatologischen Behandlung. Hautarzt 56:839-846
45. Zwingmann C (2003) Zielorientierte Ergebnismessung (ZOE) mit dem IHRES-Patientenfragebogen: eine kritische Zwischenbilanz. Rehabilitation 42:226-235